Dose Reduction in Thoracic CT

This study has been completed.
Information provided by:
University Health Network, Toronto Identifier:
First received: September 12, 2005
Last updated: April 20, 2007
Last verified: September 2005

Hypothesis: Does a 50% reduction in radiation in dose significantly affect the diagnostic quality of chest CT

Condition Intervention Phase
Device: CT Thorax
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Dose Reduction in Thoracic CT: A Comparison of on Line Automatic Dose Reduction and a 50% Reduction in Dose

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Evaluating the diagnostic quality of thoracic CT exams performed at 50% of standard dose parameters

Estimated Enrollment: 100
Study Start Date: January 2004
Estimated Study Completion Date: August 2005
Detailed Description:

Patients with Lymphoma are recruited and have a follow up CT performed at 50% of the standard exposure parameters. The studies are compared for image quality with a recent (<3 months) thoracic CT performed at standard exposure parameters.


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with Lymphoma

Exclusion Criteria:

  • No recent (<3 months) thoracic CT
  Contacts and Locations
Please refer to this study by its identifier: NCT00188461

Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada
Sponsors and Collaborators
University Health Network, Toronto
Principal Investigator: Narinder Paul, FRCP C University Health Network, Toronto
  More Information

No publications provided Identifier: NCT00188461     History of Changes
Other Study ID Numbers: 03-0875
Study First Received: September 12, 2005
Last Updated: April 20, 2007
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on April 22, 2014